Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older

NCT02464163 is registered in ClinicalTrials.gov with Protein Sciences Corporation as lead sponsor.

NCT NCT02464163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02464163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older
Lead sponsor
Protein Sciences Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2015
Completion date
August 31, 2016
Enrollment
407 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

influenza